SGK1-IN-10

SGK1-IN-10 (compound 7h) inhibits proliferation of PC3 prostate cancer cells with an IC₅₀ of 1.08 μM and LNCaP prostate cancer cells with an IC₅₀ of 1.24 μM^[1].
SGK1-IN-10 inhibits proliferation of HepG2 liver cancer cells with an IC₅₀ of 1.21 μM and shows low cytotoxicity to LX2 normal liver cells with an IC₅₀ of 10.07 μM, yielding a selectivity index of 9.15^[1].
SGK1-IN-10 (0.5-2.0 μM; 48 h) induces concentration-dependent apoptosis in PC3 prostate cancer cells, with a total apoptotic rate of 74.70% at 2.0 μM^[1].
SGK1-IN-10 (0.5-2.0 μM; 48 h) induces concentration-dependent S-phase cell cycle arrest in PC3 prostate cancer cells, with 61.48% of cells in S-phase at 2.0 μM^[1].
SGK1-IN-10 (0.5-2.0 μM; 24-48 h) inhibits migration of PC3 prostate cancer cells in a dose- and time-dependent manner^[1].
SGK1-IN-10 (0.01-10 μM; 2 h) directly binds to and stabilizes SGK1 protein in PC3 prostate cancer cells in a temperature- and concentration-dependent manner^[1].
SGK1-IN-10 (0.5-2.0 μM) dose-dependently inhibits phosphorylation of SGK1 substrates MDM2 and GSK-3β in PC3 prostate cancer cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.